Back to search

National and Kapodistrian University of Athens

Ανάπτυξη ενός κλινικά αξιοποιήσιμου πρωτοκόλλου διαφοροποίησης επαγόμενων πολυδύναμων βλαστοκυττάρων σε μεσεγχυματικά στελεχιαία κύτταρα

Abstract

dc:description

Mesenchymal stem cells (MSCs) have gained much interest during the last years, due to their immunomodulatory and regenerative properties and they are being examined as a therapeutic tool for a wide variety of diseases. The most widely used MSC- source is the bone marrow, from which, though, only a limited amount of MSCs can be produced that is usually not sufficient for clinical use. Induced pluripotent stem cells (iPSCs) can represent an alternative source of MSCs that would overcome the limitations of the adult sources. Due to their property of pluripotency they can be used for large scale production of differentiated cells with potential to be used in regenerative medicine. In the current study, we aimed at developing a clinical scale protocol for the production of MSCs from iPSC lines that had been generated with integration-free method of reprogramming and at examining the properties of the produced MSCs. Two integration-free iPSC lines were expanded in in vitro cultures without feeder cells in order to derive sufficient numbers of cells. The lines were then cultured in low attachement plates, without FGF-2 for the formation of embryoid bodies and afterwards they were cultured on gelatin with appropriate MSC differentiation medium. The derived MSCs (iPSC-MSCs) were tested with flow cytometry for the expression of MSC markers. Their multilineage differentiation potential was examined under chondrogenic, osteogenic and adipogenic cultures. Their chondrogenic capacity was further examined in comparison with MSCs from bone marrow (BM-MSCs) histologically and immunohistochemically. Their proliferative capacity was examined in comparison with BM-MSCs under parallel cultures till senescence. They were also tested for in vivo tumor formation after administration in immunoincompetent mice and for downregulation of pluripotency markers Oct3/4 and Nanog. Their genomic stability was tested with array comparative genomic hybridization (aCGH).iPSCs were efficiently differentiated in MSCs, within a time interval of 3 weeks. iPSC-MSCs are similar to BM-MSCs and express the surface antigens CD105, CD73, CD44, CD90 whereas they are negative for CD34 and CD45. In vivo, they do not induce oncogenesis in immunoincompetent mice 10 weeks after administration. They have downregulated the expression of pluripotency markers. Differentiation did not induce chromosomal aberrations and iPSC-MSCs had similar chromosomal pattern as their parental iPSCs, including 2 deletions of 3Mb that had been generated during their expansion. The deletions were not related to aberrant proliferation of cells. The proliferative capacity of iPSC-MSCs was much higher than that of BM-MSCs with cumulative population doubling being 35.7 and 28.3 versus 16.9 and 17.8 in BM-MSCs. iPSC-MSCs had up to 5.88x1010 fold expansion, while the respective number in BM-MSCs was 2.3x105. iPSC-MSCs exhibited multilineage differention potential. However, the derived chondrogenic tissues did not have the typical hyaline cartilage morphology and proteoglycan composition and displayed poor expression of Sox9 and Collagen II, in contrast to BM-MSCs.For the first time in Greece, MSC lines are derived from integration-free iPSCs under safe and efficient protocols and their properties are examined in comparison with BM-MSCs. iPSCs can be a safe source of MSCs and can be stored in iPSC-bank allowing consecutive differentiation with potential to be used clinically in the future in cell therapy. iPSC-MSCs have great similarities with BM-MSCs, but their properties need to be further investigated in preclinical models of various diseases for the elucidation of their therapeutic effects.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2021

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Sfougkataki, Eirini
  • Σφουγκατάκη, Ειρήνη

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/49111

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Sfougkataki, Eirini; Σφουγκατάκη, Ειρήνη. Ανάπτυξη ενός κλινικά αξιοποιήσιμου πρωτοκόλλου διαφοροποίησης επαγόμενων πολυδύναμων βλαστοκυττάρων σε μεσεγχυματικά στελεχιαία κύτταρα. National and Kapodistrian University of Athens, 2021. http://hdl.handle.net/10442/hedi/49111